SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cell Therapeutics (CTIC)
An SI Board Since August 1997
Posts SubjectMarks Bans Symbol
946 45 0 CTIC
Emcee:  Regis McConnell Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
221there's also this, although I post it with a big doses of salt and "letscaram(o)uche-5/19/2004
220Phase II Studies of TRISENOX in Multiple Myeloma and Myelodysplastic Syndrome YiIcebrg-5/19/2004
219[Arsenic Trioxide-Induced Death of Neuroblastoma Cells Involves Activation of Batuck-5/7/2004
218Expecting another buying op here, as CTIC missed earnings (ex one time charges) tuck-5/6/2004
217The only reason I can see for ctic's underperformance since december is the keokalani'nui-4/30/2004
216Expert Opin Pharmacother. 2004 Apr;5(4):747-65. A comparison of the benefits scaram(o)uche-4/23/2004
215TRISENOX(R) U.S. Marketing Exclusivity Extended to 2018 Wednesday April 21, 7:02nigel bates-4/21/2004
214Cell Therapeutics Initiates Phase I/II Study of CT-2106, Second Polyglutamate Drnigel bates-4/20/2004
213Here's an article (not the one I saw originally, but the only one I could fiBiomaven-4/13/2004
212I did read someplace recently (WSJ maybe?) about some study that claimed that coBiomaven-4/13/2004
211<i>which the company spent $2.2 million last year to rent, the annual repotom pope-4/13/2004
210Ouch. Do they <b>really</b> need the jet ?? ...Or the CEO ? <gnigel bates-4/13/2004
209CEO misses deadline to repay $3.5 million to Cell Therapeutics By Luke TimmermaIcebrg-4/13/2004
208The reason that I can think of is the big guys want to load it up before releasiThai Chung-4/7/2004
207Tuck, Remember that APL is a pretty niche indication - maybe 1,500 patients a yBiomaven-4/7/2004
206I found this abstract and posted it here two weeks ago. Message 19952469 At thtuck-4/7/2004
205Arsenic Trioxide in Combination with All-Trans Retinoic Acid (ATRA) Yields High Thai Chung-4/7/2004
204Thanks, Calypso.tom pope-4/1/2004
203Must have been a temporary glitch. Cell Therapeutics, Inc. and GOG Sign Landmarcaly-4/1/2004
202There's a press release by CTIC re an IND for Xyotax that's generating stom pope-4/1/2004
201testtom pope-4/1/2004
200Note another possibility is to try to co-promote or acquire Vesanoid. From EriBiomaven-3/27/2004
199ATRA is a Roche drug (trade name Vesanoid), by the way. Always good to notice tBiomaven-3/25/2004
198[ATRA/As2O3 combination for remission/maintenance therapy of APL] >>Publituck-3/24/2004
197Well it may be no more than coincidence, but I was just reading about NADPH oxidBiomaven-3/17/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News